Meet Bob – living proof that lung cancer isn’t the death sentence it once was...

LUNG cancer was once considered pretty much a death sentence. Just two decades ago, it was near-impossible to treat. Doctors had only a handful of drugs at their disposal – and most patients were given just months to live. A mere 17 per cent of those diagnosed with lung cancer in 1990 were alive a year later, and scientific progress in treating it had also stalled. Even as the discovery of new treatments for breast and bowel cancer helped boost survival rates, the outlook for those with lung cancer remained bleak. Today it is still the UK’s biggest cancer killer, accounting for one in five of all cancer deaths, but now – at last – there is reason for hope.

Over the past decade, thanks to huge leaps in scientific understanding, an arsenal of highly targeted lung cancer treatments have been developed. Now a new analysis of US data, published in The New England Journal Of Medicine, reveals promising signs that this could be leading to a drop in deaths from the most common form of the disease.

Deaths from non-small-cell lung cancer, which accounts for about eight in ten cases, have been gradually declining over the past few decades due to fewer people smoking (the main cause of lung cancer). However, from 2013, as new treatments were launched, the decline in deaths doubled, with rates plummeting by almost 20 per cent in three years.

Experts soon expect to see a similar trend in the UK, where doctors report that patients are surviving longer than ever before thanks to medical breakthroughs. ‘When I started as a consultant nearly 15 years ago, lung cancer was a next-to-impossible disease to treat,’ says Professor Sanjay Popat, consultant oncologist at London’s Royal Marsden Hospital.

‘There was no hope, people were downbeat and patients would say, “What is the point?” But we now have a much deeper understanding of the biology of the disease. We have newer treatments and we have new surgical and radiotherapy techniques.

‘And as a consequence, people who would on average pass away within less than a year historically are now living in excess of two years, three years, even five years. It is absolutely fantastic to see.’ W ITH about 47,000 people diagnosed every year in the UK, lung cancer is one of the most common types of the disease. Though smoking is thought to be responsible for about 70 per cent of cases, it can also occur in people who have never smoked due to exposure to harmful chemicals, other substances and pollution.

In its early stages, lung cancer often causes few symptoms. But as it progresses, patients may develop a persistent cough, bring up blood and experience aches, pains and breathlessness. Because of the vague symptoms early on, it is often picked up when it has already spread to other parts of the body.

‘ Once the cancer has spread beyond the lung, the majority of patients will die from their disease,’ explains Professor Charles Swanton, Cancer Research UK’s chief clinician and a lung cancer doctor at University College London Hospitals NHS Foundation Trust.

Previously, people with advanced lung cancer would be treated with chemotherapy drugs. However, they were rarely effective and were accompanied by gruelling side effects, including sickness and fatigue, that tarnished the last months of patients’ lives.

But over the past ten years, targeted drugs, which come in pill form and work by interfering with the way cancerous cells multiply and grow, have gained UK approval for the treatment of advanced non-smallcell lung cancer. Now, samples taken from tumours are tested to see if there are specific genetic mutations that can be targeted with these newly available drugs.

Prof Popat says: ‘ About 15 to 20 per cent of patients with advanced lung cancer have some sort of genetic change in their tumour that can be targeted.

‘That isn’t a genetic change that is i nherited from their parents, or one that they can pass on to their children, but it is a genetic change in the tumour itself, driving it to grow and divide and multiply and replicate. There are now simple, straightforward tablets that can switch off the effect of that genetic change, causing the whole cancer to implode.’

Some targeted lung cancer drugs, including erlotinib and gefitinib, are directed at a mutation called the epidermal growth factor receptor (EGFR), which causes tumours to grow rapidly.

About ten to 15 per cent of nonsmall- cell lung cancer patients have this mutation, and studies have shown these treatments can add months to lives. Earlier this month, osimertinib – also called Tagrisso – became the latest drug forEGF R-positive non-small-cell lung cancer to be approved by UK regulator the National Institute for Health and Care Excellence (Nice) after trials showed it could stall cancer growth for even longer. According to Prof Swan ton, about half of patients with an EGFR mutation now live for three years or more thanks to such drugs. ‘ When you’ve got a patient with an EGFR mutant lung cancer, you breathe a sigh of relief because you know there is a very good chance they will benefit from this new class of drugs,’ Prof Swanton says. More recently, immunotherapy treatments, which stimulate the immune system to attack cancerous cells, are helping even more lung cancer patients live for longer. Pembrolizumab, also known as Keytruda, was in 2016 the first immunotherapy treatment for nonsmall-cell lung cancer approved for use on the NHS. It affects a molecule called PD- 1, which is found on the surface of T-cells – a type of white blood cell that help the body fight infection. This activates them to attack tumour cells.

According to data presented earlier this month at the European Society for Medical Oncology’s virtual congress, almost a third of patients with advanced non-smallcell lung cancer treated with pembrolizumab lived longer than five years. This compares with just 16 per cent of those treated with chemotherapy. ‘ It’s a complete game-changer,’ says Prof Popat.

And in cancer clinics, doctors are already seeing how effective these drugs can be. ‘We’ve had miraculous outcomes,’ says Prof Swanton. ‘Patients are alive today who would not have been a decade ago.’

One such patient is Bob Pain, from near Epsom in Surrey. The 65-year-old, who runs a graphics printing business, was diagnosed in 2015 after scans picked up a shadow on his left lung. The ex- smoker underwent surgery to have half the lung removed, followed by chemotherapy. Tests showed he was free of cancer, but in early 2018 he began developing worrying symptoms.

‘I started to get pain in my back and hip,’ Bob recalls. ‘I had just started doing yoga in an effort to get fitter after my illness, so put it down to that. Then, on Good Friday, I fainted suddenly.

‘My wife Lisa called an ambulance and I was taken to A& E, where they did loads of tests.

‘The doctors eventually let me go, as there didn’t seem to be anything wrong. But when I told my chest consultant, he organised a scan, which revealed a big mass on my lung and my liver.’

The cancer had returned, and this time it had spread to his liver and bones – stage four. He was left in agony and struggled to move.

In June 2018, Bob started treatment with pembrolizumab, covered privately by his health insurance – and after just a few months, scans showed the tumours in his liver and lung had reduced by half. ‘It was staggering,’ Bob says. ‘It felt like I’d won the Lotto jackpot. It was just incredible.’

Recent scans have shown that Bob is clear of cancer – even in his bones – and the difference in his health is remarkable. ‘Now I do yoga two or

The difference was staggering. I felt like I had won the Lotto. It was incredible